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background:  Glycosylated proteins participate in multiple cellular processes including inflammation, immunity, signaling, and metabolism. 
Using a novel plasma glycan biomarker (GlycA) to identify N-acetyl groups of several endogenous acute phase reactants, we examined the 
association between GlycA and mortality among initially healthy individuals.
Methods:  A total of 39,521 participants (2,563 deaths) in JUPITER (NCT00239681; AstraZeneca) and Women’s Health Study (WHS; 
NCT00000479) had GlycA quantified by NMR spectroscopy (LipoScience). Cox regression models were adjusted for clinical risk factors 
(Model 1) and further adjusted for hsCRP (Model 2).
Results:  Data were analyzed from 12,249 JUPITER and 27,272 WHS participants (maximum follow-up 5.0 and 18.8 years, respectively). 
In unadjusted models, GlycA was significantly associated with all-cause and cardiovascular (CV) mortality (Table). In JUPITER, adjusted 
HRs for all-cause and CV mortality for top vs bottom quartile GlycA were 2.65 (1.87-3.76, p <.0001) and 1.28 (0.83-1.98, p = 0.261), 
respectively. For WHS, these were 1.28 (1.11-1.48, p = 0.001) and 1.28, (0.82-1.99, p = 0.112). The association with all-cause mortality 
persisted but was attenuated after adjustment for hsCRP. Mortality HRs were similar to those for hsCRP.
conclusion:  Among 39,521 initially healthy individuals with up to 18 years of follow-up, elevated baseline levels of GlycA, a novel 
biomarker of circulating glycoproteins, predicted future all-cause mortality.
GlycA and all-cause and cardiovascular mortality in JUPITER and WHS.
JUPITER (N=12,249) WHS (N=27,272)
Quartile 4 vs 1 (HR [95% CI]) p for trend Quartile 4 vs 1 (HR [95% CI]) p for trend
All-Cause Mortality
Unadjusted 2.77 (1.99, 3.86) <0.0001 1.88 (1.67, 2.11) <0.0001
Model 1 2.65 (1.87, 3.76) <0.0001 1.28 (1.11, 1.48) 0.0005
Model 2 2.17 (1.47, 3.21) <0.0001 1.14 (0.97, 1.33) 0.11
CVD Mortality
Unadjusted 1.63 (1.09, 2.45) 0.0102 2.72 (1.89, 3.90) <0.0001
Model 1 1.28 (0.83, 1.98) 0.21 1.28 (0.82, 1.99) 0.15
Model 2 1.14 (0.70, 1.84) 0.56 1.18 (0.73, 1.90) 0.36
